Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies

Overview

Journal J Hepatocell Carcinoma

Date 2021 Sep 30

PMID 34589446

Citations 12

Authors

Timothy C Huber

Teodora Bochnakova

Yilun Koethe

Brian Park

Khashayar Farsad

Affiliations

Soon will be listed here.

Abstract

Percutaneous ablation is a mainstay of treatment for early stage, unresectable hepatocellular carcinoma (HCC). Recent advances in technology have created multiple ablative modalities for treatment of this common malignancy. The purpose of this review is to familiarize readers with the technical and clinical aspects of both existing and emerging percutaneous treatment options for HCC.

Citing Articles

Augmented Reality for Surgical Navigation: A Review of Advanced Needle Guidance Systems for Percutaneous Tumor Ablation.

Evans M, Kang S, Bajaber A, Gordon K, Martin 3rd C Radiol Imaging Cancer. 2025; 7(1):e230154.

PMID: 39750112 PMC: 11791678. DOI: 10.1148/rycan.230154.

Anti-tumor efficacy of : Suppressing liver cancer by targeting tumor-associated macrophages.

Kathuria I, Singla B World J Gastroenterol. 2024; 30(38):4249-4253.

PMID: 39493325 PMC: 11525873. DOI: 10.3748/wjg.v30.i38.4249.

Threatment Strategies for Recurrent Hepatocellular Carcinoma Patients: Ablation and its Combination Patterns.

Zhao Y, Bai J, Wang X, Zhang Y, Yan X, Qi J J Cancer. 2024; 15(8):2193-2205.

PMID: 38495485 PMC: 10937274. DOI: 10.7150/jca.93885.

Matrin-3 acts as a potential biomarker and promotes hepatocellular carcinoma progression by interacting with cell cycle-regulating genes.

He H, Jamal M, Zeng X, Lei Y, Xiao D, Wei Z Cell Cycle. 2024; 23(1):15-35.

PMID: 38252499 PMC: 11005806. DOI: 10.1080/15384101.2024.2305535.

PD1 and TIM3 Expression is Associated with Very Early Hepatocellular Carcinoma Recurrence After Percutaneous Thermal Ablation.

Ghelfi J, Macek Jilkova Z, Sengel C, Brusset B, Teyssier Y, Costentin C J Hepatocell Carcinoma. 2024; 11:39-50.

PMID: 38223553 PMC: 10787562. DOI: 10.2147/JHC.S443134.

References

Padia S, Johnson G, Yeung R, Park J, Hippe D, Kogut M . Irreversible Electroporation in Patients with Hepatocellular Carcinoma: Immediate versus Delayed Findings at MR Imaging. Radiology. 2015; 278(1):285-94. DOI: 10.1148/radiol.2015150031. View

Goldberg S, Gazelle G, Halpern E, Rittman W, Mueller P, Rosenthal D . Radiofrequency tissue ablation: importance of local temperature along the electrode tip exposure in determining lesion shape and size. Acad Radiol. 1996; 3(3):212-8. DOI: 10.1016/s1076-6332(96)80443-0. View

Han X, Xu K, Taratula O, Farsad K . Applications of nanoparticles in biomedical imaging. Nanoscale. 2019; 11(3):799-819. PMC: 8112886. DOI: 10.1039/c8nr07769j. View

Narayanan G, Bhatia S, Echenique A, Suthar R, Barbery K, Yrizarry J . Vessel patency post irreversible electroporation. Cardiovasc Intervent Radiol. 2014; 37(6):1523-9. DOI: 10.1007/s00270-014-0988-9. View

Zeng J, Liu G, Li Z, Yang Y, Fang G, Li R . The Safety and Efficacy of Irreversible Electroporation for Large Hepatocellular Carcinoma. Technol Cancer Res Treat. 2016; 16(1):120-124. PMC: 5616122. DOI: 10.1177/1533034616676445. View

Park B, Hunt S, Nadolski G, Gade T . Augmented reality improves procedural efficiency and reduces radiation dose for CT-guided lesion targeting: a phantom study using HoloLens 2. Sci Rep. 2020; 10(1):18620. PMC: 7596500. DOI: 10.1038/s41598-020-75676-4. View

Wood B, Kruecker J, Abi-Jaoudeh N, Locklin J, Levy E, Xu S . Navigation systems for ablation. J Vasc Interv Radiol. 2010; 21(8 Suppl):S257-63. PMC: 2921632. DOI: 10.1016/j.jvir.2010.05.003. View

Sutter O, Calvo J, Nkontchou G, Nault J, Ourabia R, Nahon P . Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series. Radiology. 2017; 284(3):877-886. DOI: 10.1148/radiol.2017161413. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

10.

Cheung T, Ma K, She W . A review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis. Hepatobiliary Surg Nutr. 2021; 10(2):193-209. PMC: 8050587. DOI: 10.21037/hbsn.2020.03.11. View

11.

Singh P, Toom S, Avula A, Kumar V, Rahma O . The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2020; 7:11-17. PMC: 7022138. DOI: 10.2147/JHC.S187121. View

12.

Vogl T, Nour-Eldin N, Hammerstingl R, Panahi B, Naguib N . Microwave Ablation (MWA): Basics, Technique and Results in Primary and Metastatic Liver Neoplasms - Review Article. Rofo. 2017; 189(11):1055-1066. DOI: 10.1055/s-0043-117410. View

13.

Liu F, Liang P, Yu X, Lu T, Cheng Z, Lei C . A three-dimensional visualisation preoperative treatment planning system in microwave ablation for liver cancer: a preliminary clinical application. Int J Hyperthermia. 2013; 29(7):671-7. DOI: 10.3109/02656736.2013.834383. View

14.

Verloh N, Jensch I, Lurken L, Haimerl M, Dollinger M, Renner P . Similar complication rates for irreversible electroporation and thermal ablation in patients with hepatocellular tumors. Radiol Oncol. 2019; 53(1):116-122. PMC: 6411026. DOI: 10.2478/raon-2019-0011. View

15.

Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Mukaida N, Matsushima K . Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma. Int J Cancer. 2009; 126(9):2164-74. DOI: 10.1002/ijc.24882. View

16.

Abi-Jaoudeh N, Venkatesan A, Sterren W, Radaelli A, Carelsen B, Wood B . Clinical experience with cone-beam CT navigation for tumor ablation. J Vasc Interv Radiol. 2015; 26(2):214-9. PMC: 4315943. DOI: 10.1016/j.jvir.2014.10.049. View

17.

Peng P, Hu H, Liu P, Xu L . Neoantigen-specific CD4 T-cell response is critical for the therapeutic efficacy of cryo-thermal therapy. J Immunother Cancer. 2020; 8(2). PMC: 7497524. DOI: 10.1136/jitc-2019-000421. View

18.

Jiang C, Cheng G, Liao M, Huang J . Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis. World J Surg Oncol. 2021; 19(1):81. PMC: 7980330. DOI: 10.1186/s12957-021-02188-4. View

19.

Littrup P, Aoun H, Adam B, Krycia M, Prus M, Shields A . Percutaneous cryoablation of hepatic tumors: long-term experience of a large U.S. series. Abdom Radiol (NY). 2016; 41(4):767-80. DOI: 10.1007/s00261-016-0687-x. View

20.

Llovet J, De Baere T, Kulik L, Haber P, Greten T, Meyer T . Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021; 18(5):293-313. DOI: 10.1038/s41575-020-00395-0. View